Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Islet Studies

ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation

  1. Mallikarjuna R. Metukuri1,2,
  2. Pili Zhang1,
  3. Mahesh K. Basantani1,
  4. Connie Chin1,
  5. Rachel E. Stamateris1,
  6. Laura C. Alonso1,
  7. Karen K. Takane1,
  8. Roberto Gramignoli3,
  9. Stephen C. Strom3,
  10. Robert M. O’Doherty1,
  11. Andrew F. Stewart1,
  12. Rupangi C. Vasavada1,
  13. Adolfo Garcia-Ocaña1 and
  14. Donald K. Scott1⇓
  1. 1Department of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania
  2. 2Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina
  3. 3Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania
  1. Corresponding author: Donald K. Scott, dks23{at}pitt.edu.
Diabetes 2012 Aug; 61(8): 2004-2015. https://doi.org/10.2337/db11-0802
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    ChREBP abundance in rodent and human β-cells is comparable with liver. A: Relative mRNA abundance from rat or human liver or pancreatic β-cells, using quantitative RT-PCR and species-specific primers. Results were normalized to β-actin and are the means of three independent experiments ± SEM. B: Relative abundance of ChREBP protein in immunoblots from whole protein extracts from liver, primary hepatocytes, or isolated islets from rats or humans. β-Actin is used as a loading control, and results are representative of three independent experiments. C: Immunofluorescence using species-specific antibodies against ChREBP in dispersed rat and human islets cells and in a section of a mouse pancreas using antibodies against ChREBP (red), insulin (green), and with a nuclear stain (DAPI). The far right column confirms that red ChREBP-dependent fluorescence is not a result of the nonspecific binding of secondary antibody. Results shown are representative of three independent experiments. (A high-quality digital representation of this figure is available in the online issue.)

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    ChREBP is required for glucose-stimulated rat β-cell proliferation. Rat islets were isolated and dispersed by trypsinization and treated for 72 h in 5.5 mmol/L glucose with control or ChREBP-specific Accell siRNA. RNA was isolated and subjected to quantitative RT-PCR with primers specific for ChREBP and β-actin (A), or protein was isolated and subjected to immunoblotting with antibodies directed against either ChREBP or β-actin (B). Results in A are the means ± SE; n = 3; *P < 0.05; results in B are representative of two independent experiments with identical results. C: Dispersed rat islets cells treated with Accell siRNA were cultured on coverslips in either 5.5 or 20 mmol/L glucose for 72 h. BrdU was added for the last 36 h. Cells were fixed and stained with anti-insulin (green) and BrdU (red) antibodies, and nuclei were stained with DAPI (blue). D: Shown are the means ± SE of the percentage of BrdU-positive:insulin-positive cells, counted in a blinded fashion, and normalized to the low glucose control (average = 0.7%), from four independent experiments (*P < 0.05). At least 1,300 insulin-positive cells were counted for each treatment group. E: Dispersed islets from control (C57BL/6J) or ChREBP−/− mice on the same genetic background were cultured for 72 h in either 5.5 or 20 mmol/L glucose, and BrdU was added for the last 48 h. Cells were fixed and stained with anti-insulin (green) and BrdU (red) antibodies, and nuclei were stained with DAPI (blue). F: Results are the means ± SE of the percentage of BrdU-positive:insulin-positive cells, counted in a blinded fashion, and normalized to the low glucose control (average = 0.3%), from four control and four ChREBP−/− animals (*P < 0.05). An average of 1,988 ± 265 insulin-positive cells were counted for each treatment group. WT, wild type; n.s., not significant; Con, control; siCon, siControl. (A high-quality digital representation of this figure is available in the online issue.)

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Depletion of ChREBP in INS-1–derived 832/13 cells inhibits glucose-stimulated proliferation. INS-1–derived 832/13 cells were transfected with either ChREBP-specific or control siRNA in 11 mmol/L glucose. After 48 h, media were switched to 3 mmol/L glucose for 6 h and then incubated in 3 or 15 mmol/L glucose for an additional 16 h. Total RNA or protein was extracted and used to determine relative levels of ChREBP by quantitative RT-PCR after normalization to β-actin (A) or by immunoblotting relative to β-actin (B), respectively. Pklr mRNA expression was determined in C. In addition, proliferation rates were determined by [3H]thymidine incorporation (D). Results are expressed as the means ± SE (n = 3 to 5; *P < 0.05; n.s., not significant).

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Depletion of ChREBP decreases mRNA expression of cell cycle regulators. INS-1–derived 832/13 cells were transfected for 48 h with either ChREBP-specific or scrambled siRNAs. Cells were pretreated in 3 mmol/L glucose for 6 h and then cultured in 3 or 15 mmol/L glucose for 16 h. Relative mRNA levels of the indicated genes were determined by quantitative RT-PCR and normalized to actin. Shown are the means ± SE (n = 3 to 4; *P < 0.05; n.s., not significant).

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Depletion of ChREBP leads to decreased protein expression of cell cycle regulators. INS-1–derived 832/13 cells were transfected for 48 h with either ChREBP-specific or scrambled siRNAs. Cells were pretreated in 3 mmol/L glucose for 6 h and then cultured in 3 or 15 mmol/L glucose for 16 h. Immunoblot analysis was used to determine the relative protein expression of the indicated cell cycle regulators. Shown are representative autoradiograms for cyclins (A) and cyclin-dependent kinases (B). C–H: The results of densitometry from immunoblots as in A and B are presented as means from three to four separate experiments (± SE; *P < 0.05; #P < 0.05 compared with 3 mmol/L glucose control; n.s., not significant).

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Overexpression of ChREBP amplifies glucose-stimulated β-cell proliferation. Transduction of adenovirus expressing ChREBP in INS-1–derived 832/13 cells (A) or isolated rat islets (C) led to robust expression of ChREBP as determined by immunoblotting. Shown are blots representative of two independent experiments with identical results. B: INS-1–derived 832/13 cells were treated with adenovirus expressing ChREBP, or GFP as a control, for 2 h and cultured for an additional 22 h in 11 mmol/L glucose. Cells were then pretreated for 6 h in 3 mmol/L glucose, and after 16 h of culture in either 3 or 15 mmol/L glucose, the relative amount [3H]thymidine incorporation was determined. Results are expressed as means ± SE (n = 3 to 5; *P < 0.05). C–E: Dispersed rat islet cells were transduced with adenovirus expressing ChREBP or GFP for 2 h. Cells were cultured on coverslips in medium containing 5.5 mmol/L glucose for 24 h, at which time the high glucose group was adjusted to 20 mmol/L glucose and the cells were cultured for an additional 60 h. D: BrdU was added for the last 36 h, and cells were fixed and stained for insulin (green) or BrdU (red) and DAPI (blue). E: Cells were counted in a blinded fashion, and the results are expressed as a percentage of insulin:BrdU-positive cells (± SE; n = 4; *P < 0.05). At least 1,500 cells were counted for each treatment group. siCon, siControl. (A high-quality digital representation of this figure is available in the online issue.)

  • FIG. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Overexpression of ChREBP increases expression of cyclins A and E. INS-1–derived 832/13 were transduced with adenoviruses expressing either GFP or ChREBP as in Fig. 6 and were cultured for 18 h in 3 or 15 mmol/L glucose and processed for immunoblotting. A–F: Representative immunoblots of the indicated proteins are shown, with results of densitometry, normalized to β-actin shown above (means ± SE; n = 3 to 4; *P < 0.05).

  • FIG. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    ChREBP regulates glucose-stimulated proliferation in human β-cells. Isolated human islets were dispersed by trypsinization and treated with control or ChREBP-specific Accell siRNA in 5.5 mmol/L glucose, and after 72 h, the relative abundance of ChREBP mRNA was determined by quantitative RT-PCR (A) or protein was isolated and subjected to immunoblotting with antibodies directed against either ChREBP or β-actin (B). Results in A are the means ± SE (n = 3; *P < 0.05); results in B are representative of two independent experiments with identical results. C: Dispersed human islets cells treated with Accell siRNA were cultured on coverslips in either 5.5 or 20 mmol/L glucose for 72 h. BrdU was added for the last 48 h. Cells were fixed and stained with anti-insulin (green) and BrdU (red) antibodies, and nuclei were stained with DAPI (blue) (see Supplementary Fig. 1). At least 1,500 cells were counted for each treatment group. Shown are the means ± SE of the percentage of BrdU-positive:insulin-positive cells, counted in a blinded fashion, normalized to the low glucose control (average = 0.3%), from four independent experiments (*P < 0.05). D and E: Dispersed human islet cells were transduced with adenovirus expressing ChREBP or GFP and were treated exactly as described for isolated rat islet cells in Fig. 6, except BrdU was added 48 h before the end of the experiment. D: A representative immunoblot is shown with antibodies specific for either ChREBP or β-actin as indicated. Cells were fixed and stained with antibodies against insulin (green) and BrdU (red), with nuclei stained with DAPI (blue) (see Supplementary Fig. 1). E: Cells were counted in a blinded fashion, and the results are expressed as a percentage of insulin:BrdU-positive cells, normalized to the low glucose control, which averaged 0.3% (means ± SE; n = 4; *P < 0.05). At least 1,500 β-cells were counted for each condition in each of four independent experiments. Con, control; n.s., not significant.

Tables

  • Figures
  • TABLE 1
PreviousNext
Back to top
Diabetes: 61 (8)

In this Issue

August 2012, 61(8)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation
Mallikarjuna R. Metukuri, Pili Zhang, Mahesh K. Basantani, Connie Chin, Rachel E. Stamateris, Laura C. Alonso, Karen K. Takane, Roberto Gramignoli, Stephen C. Strom, Robert M. O’Doherty, Andrew F. Stewart, Rupangi C. Vasavada, Adolfo Garcia-Ocaña, Donald K. Scott
Diabetes Aug 2012, 61 (8) 2004-2015; DOI: 10.2337/db11-0802

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

ChREBP Mediates Glucose-Stimulated Pancreatic β-Cell Proliferation
Mallikarjuna R. Metukuri, Pili Zhang, Mahesh K. Basantani, Connie Chin, Rachel E. Stamateris, Laura C. Alonso, Karen K. Takane, Roberto Gramignoli, Stephen C. Strom, Robert M. O’Doherty, Andrew F. Stewart, Rupangi C. Vasavada, Adolfo Garcia-Ocaña, Donald K. Scott
Diabetes Aug 2012, 61 (8) 2004-2015; DOI: 10.2337/db11-0802
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Pancreatic β-Cell–Specific Deletion of VPS41 Causes Diabetes Due to Defects in Insulin Secretion
  • Retinol-Binding Protein 4 Activates STRA6, Provoking Pancreatic β-Cell Dysfunction in Type 2 Diabetes
  • Loss of Furin in β-Cells Induces an mTORC1-ATF4 Anabolic Pathway That Leads to β-Cell Dysfunction
Show more Islet Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.